|

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

RECRUITINGPhase 4Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 4
SponsorEli Lilly and Company
Started2026-03-09
Est. completion2030-05
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations9 sites
View on ClinicalTrials.gov →

NCT07218341

Summary

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria:

* This is not applicable to this study

Conditions3

CancerChronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic

Interventions2

IdelalisibPirtobrutinib

Locations9 sites

Mitchell Cancer Institute
Mobile, Alabama, 36693
334-660-5108
Arizona Oncology Associates, P.C. - HOPE
Tucson, Arizona, 85711
520-886-0206
Cancer Specialists, LLC
Jacksonville, Florida, 32256
904-538-4488
Minnesota Oncology Hematology, P.A.
Coon Rapids, Minnesota, 55433
612-884-6300
Cayuga Cancer Center
Ithaca, New York, 14850
Cynthia Davis

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.